2.0M XNAS Volume
XNAS 02 Apr, 2025 12:06 PM (EDT)
Viatris Inc Key Metrics
Default
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Mid Valuation
Technically Bearish
Weak Stock
These stocks are the ones with poor quality and weak financial and technical aspects. However, these stocks have a medium valuation score. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
8Positive13Negative
38.1% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Viatris Inc Stock Price Analysis
Day Price Range | 8.6 (LTP) 8.58.7 LowHigh |
Week Price Range | 8.6 (LTP) 8.59.1 LowHigh |
Month Price Range | 8.6 (LTP) 8.59.7 LowHigh |
52 Week Price Range | 8.6 (LTP) 8.513.6 LowHigh |
Viatris Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Miss
Viatris Inc's Revenue was lower than average estimate 3 times in past 3 years
Consensus Recommendation
9 ANALYST Recommendations
HOLD
The consensus recommendation from 9 analysts for Viatris Inc is HOLD
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Viatris Inc Stock Analysis
Viatris Inc stock analysis with key metrics, changes, and trends.
Viatris Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $14,739.3 M | 4.46% | negative |
| |
Annual Net Profit | $634.2 M | 1259.41% | negative |
| |
Price to Earning Ratio | -16.26 | - | negative |
| |
Stock Price | $8.64 | -27.64% | negative |
| |
Quarterly Revenue | $3,528.1 M | 8.06% | negative |
| |
Quarterly Net profit | $516.5 M | 32.54% | positive |
| |
Debt to Equity Ratio | 0.77 | - | positive |
| |
Return on Equity(ROE) | -3.24 % | -3.24% | negative |
| |
Mutual Fund Holding | 63.47 % | -1.55% | negative |
| |
Promoter Share Holding | 0.73 % | 0.23% | positive |
| |
Interest Coverage Ratio | -0.13 | - | negative |
| |
Institutional Holding | 83.39 % | 0% | neutral |
|
Loading data..
Viatris Inc - Company Profile
What does Viatris Inc do?
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Viatris Inc Management structure
All Gross Remunerations are in USD
Viatris Inc Board of directors
All Gross Remunerations are in USD